Axovant deepens gene therapy pipeline with Benitec deal

Axovant Sciences Ltd. (NASDAQ:AXON) broadened its gene therapy pipeline by obtaining exclusive, worldwide rights from Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) to BB-301. Axovant plans to start a placebo-controlled clinical trial next year of

Read the full 333 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE